NASDAQ · SERVICES-TESTING LABORATORIES · LARGE CAP
Neogenomics, Inc. NEO
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$727.3M
▲ 10.1% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-12.4%
Net margin · FY25
-14.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 727.3M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 15 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-12.4%
Return on equity, FY2025
ROE
Operating margin-15.9%
Net margin-14.9%
Return on assets-7.2%
Each USD of equity lost 12 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+10.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+12.6%
+10.4%
+22.0%
+22.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years+14.3%
Change, 10 years+69.0%
The share count grew 14% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2025
Total assetsUSD 1.4B
EquityUSD 836.6M
CashUSD 159.6M
Gross debtUSD 341.9M
Net debtUSD 182.2M
Current ratio4.26×
Net debt stands at 22% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.7
0.7
0.6
0.5
0.5
0.4
0.4
0.3
0.2
0.2
0.1
0.1
0.1
0.1
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.2
−0.1
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Income tax $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
−0.04
0.02
0.04
0.00
−0.03
−0.09
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−12.4
−8.5
−9.1
−13.7
−0.9
0.7
1.9
1.1
−0.2
−3.3
−1.9
2.8
13.1
0.9
−26.1
−105.4
Shares out B
0.13
0.13
0.13
0.13
0.12
0.11
0.10
0.09
0.08
0.08
0.08
0.06
0.05
0.05
0.04
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed